Enhancing glioblastoma treatment through the integration of tumor-treating fields
Glioblastoma (GBM) represents a significant therapeutic challenge due to its aggressive nature. Tumor Treating Fields (TTFields) present a promising approach to GBM therapy. The primary mechanism of TTFields, an antimitotic effect, alongside numerous indirect effects including increased cell membran...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1274587/full |
| _version_ | 1797658740624719872 |
|---|---|
| author | Katarzyna Szklener Mateusz Bilski Karolina Nieoczym Dominika Mańdziuk Sławomir Mańdziuk |
| author_facet | Katarzyna Szklener Mateusz Bilski Karolina Nieoczym Dominika Mańdziuk Sławomir Mańdziuk |
| author_sort | Katarzyna Szklener |
| collection | DOAJ |
| description | Glioblastoma (GBM) represents a significant therapeutic challenge due to its aggressive nature. Tumor Treating Fields (TTFields) present a promising approach to GBM therapy. The primary mechanism of TTFields, an antimitotic effect, alongside numerous indirect effects including increased cell membrane permeability, signifies their potential in combination with other treatment modalities. Current combinations often include chemotherapy, particularly with temozolomide (TMZ), however, emerging data suggests potential synergy with targeted therapies, radiotherapy, and immunotherapy as well. TTFields display minimal side effects, predominantly skin-related, posing no significant barrier to combined therapies. The effectiveness of TTFields in GBM treatment has been demonstrated through several post-registration studies, advocating for continued research to optimize overall survival (OS) and progression-free survival (PFS) in patients, as opposed to focusing solely on quality of life. |
| first_indexed | 2024-03-11T18:03:42Z |
| format | Article |
| id | doaj.art-efb705e18d19405fb73f0efe54bfa470 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T18:03:42Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-efb705e18d19405fb73f0efe54bfa4702023-10-17T08:48:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-10-011310.3389/fonc.2023.12745871274587Enhancing glioblastoma treatment through the integration of tumor-treating fieldsKatarzyna Szklener0Mateusz Bilski1Karolina Nieoczym2Dominika Mańdziuk3Sławomir Mańdziuk4Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, PolandDepartment of Radiotherapy, Medical University of Lublin, Lublin, PolandStudent Scientific Association at the Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, PolandStudent Scientific Association at the Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, PolandDepartment of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, PolandGlioblastoma (GBM) represents a significant therapeutic challenge due to its aggressive nature. Tumor Treating Fields (TTFields) present a promising approach to GBM therapy. The primary mechanism of TTFields, an antimitotic effect, alongside numerous indirect effects including increased cell membrane permeability, signifies their potential in combination with other treatment modalities. Current combinations often include chemotherapy, particularly with temozolomide (TMZ), however, emerging data suggests potential synergy with targeted therapies, radiotherapy, and immunotherapy as well. TTFields display minimal side effects, predominantly skin-related, posing no significant barrier to combined therapies. The effectiveness of TTFields in GBM treatment has been demonstrated through several post-registration studies, advocating for continued research to optimize overall survival (OS) and progression-free survival (PFS) in patients, as opposed to focusing solely on quality of life.https://www.frontiersin.org/articles/10.3389/fonc.2023.1274587/fullglioblastomaTTFtumor treating fieldsGBMcancer treatment |
| spellingShingle | Katarzyna Szklener Mateusz Bilski Karolina Nieoczym Dominika Mańdziuk Sławomir Mańdziuk Enhancing glioblastoma treatment through the integration of tumor-treating fields Frontiers in Oncology glioblastoma TTF tumor treating fields GBM cancer treatment |
| title | Enhancing glioblastoma treatment through the integration of tumor-treating fields |
| title_full | Enhancing glioblastoma treatment through the integration of tumor-treating fields |
| title_fullStr | Enhancing glioblastoma treatment through the integration of tumor-treating fields |
| title_full_unstemmed | Enhancing glioblastoma treatment through the integration of tumor-treating fields |
| title_short | Enhancing glioblastoma treatment through the integration of tumor-treating fields |
| title_sort | enhancing glioblastoma treatment through the integration of tumor treating fields |
| topic | glioblastoma TTF tumor treating fields GBM cancer treatment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1274587/full |
| work_keys_str_mv | AT katarzynaszklener enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields AT mateuszbilski enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields AT karolinanieoczym enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields AT dominikamandziuk enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields AT sławomirmandziuk enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields |